Clinical review report: Dupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.) indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those t...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, June 2020
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable |
---|---|
Physical Description: | 1 PDF file (127 pages) illustrations |